

Canaan

Peter Farina

Executive in Residence / East Coast
Since 2008

Peter works with great entrepreneurs and scientists to bring innovative medicines to patients. A Canaan Executive in Residence since 2008, Peter has been instrumental in identifying and evaluating investment opportunities in healthcare sciences for the firm. Passionate about R&D in the fields of chemistry and biology, Peter's accomplishments in drug research include the successful development and registration of Viramune® (nevirapine) and Aptivus® for HIV, Atrovent® HFA for COPD/emphysema and Jardiance® (empagliflozin) for diabetes.

Prior to joining Canaan, Peter served as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, where he was responsible for the North American development of drugs in the therapeutic areas of immunology/inflammation, virology and cardio/metabolic diseases. Peter also served as vice president of research, director of inflammatory diseases and director of biochemistry during his 28-year career with the company. Previously, Peter worked on the development of immunodiagnostics for the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation.

Peter currently serves as the co-chair and board member of Connecticut United for Research Excellence (CURE); the advisory board of the University of Connecticut School of Pharmacy, member of the NIH Blueprint Neurotherapeutics Network (BPN) steering committee; Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a non-profit company working on neglected diseases. He also advises several biotech companies with a China focus. Peter holds a Ph.D. in organic chemistry from SUNY Buffalo, and completed postdoctoral work in bioorganic chemistry at Pennsylvania State University. He also received an honorary Ph.D. from the University of Connecticut.

About Canaan

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With \$5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan's focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health and medtech. To learn more about our people and our portfolio, please visit canaan.com.